IVONESCIMAB combined with chemotherapy significantly improves overall survival for patients with advanced biliary tract cancer. In the randomized, double-blind, Phase III HARMONi-GI1 trial, investigators compared frontline systemic therapy combining the bispecific antibody ivonescimab alongside gemcitabine and cisplatin against durvalumab combined with the same chemotherapy backbone. The intention-to-treat population enrolled 682 previously untreated adults presenting with locally advanced or metastatic intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer. Over a median follow-up of 14.3 months, dual blockade of programmed cell death protein 1 and vascular endothelial growth factor established unprecedented clinical advantages across primary and secondary endpoints in a malignancy historically defined by rapid progression and restricted therapeutic durability.
Patients assigned to the ivonescimab regimen achieved a median overall survival of 14.9 months compared to 12.1 months in the active control arm, representing a statistically significant 25% reduction in the hazard of death. Landmark survival assessments reinforced this durability, with 12-month overall survival rates reaching 59.7% with ivonescimab versus 50.7% with durvalumab, and 18-month rates sustaining at 44.0% versus 32.5%. Key secondary endpoints confirmed parallel gains across the study cohort. Median progression-free survival expanded to 8.4 months in the experimental group compared to 5.8 months among control participants. Furthermore, evaluating ivonescimab in biliary tract cancer demonstrated an objective response rate of 53.8% versus 32.5% in the comparator arm, yielding an overall disease control rate of 91.5% compared to 77.8%.
Safety assessments revealed comparable tolerability profiles between both therapeutic combinations. Serious treatment-emergent adverse events occurred in 43.4% of patients receiving ivonescimab compared to 43.7% receiving durvalumab, while high-grade immune-related adverse events remained identical at 4.1% in each treatment arm. The absence of unexpected toxicities confirms that concurrent receptor engagement delivers enhanced antitumor activity without exacerbating systemic immune toxicities. Because HARMONi-GI1 represents the first Phase III trial demonstrating overall survival superiority against an active chemoimmunotherapy standard of care, these data establish ivonescimab in biliary tract cancer as an emerging clinical benchmark for oncologists managing advanced hepatobiliary disease.
Reference
Zhou J et al. Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: A randomized, controlled, double-blinded, phase 3 trial (HARMONi-GI1). ESMO Congress. 2026;Abstract LBA8.
Featured Image: vachiravit on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
